Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation

Fig. 6

Inhibition of IRE1α reverses bortezomib-increased bone volume and osteoblast number in mice. a A schematic diagram showing the treatment protocol. Five-week-old C57BL/KaLwRij mice were treated with vehicle (Veh, n = 3), bortezomib (0.3 mg/kg, n = 5), and bortezomib combined with MKC3946 (100 mg/kg, n = 3) for 7 consecutive days. On day 8, mice were sacrificed, microCT, and immunohistochemical staining used to analyze bone parameters. b Three-dimensional reconstructions of microCT scans of the representative femur from vehicle-, bortezomib-, and bortezomib combined with MKC3946-treated naive mice. c–f MicroCT analysis of the trabecular bone volume [BV/TV (%)] (c), and trabecular thickness [Tb.Th (/mm2)] (d), trabecular number [Tb.N (/mm)] (e), and trabecular separation [Tb.Sp (μm)] (f) of the femur of mice treated with vehicle, bortezomib, and bortezomib combined with MKC3946. g Histograms showing osteoblast number [Ob.N/BS (/mm)] in mice treated with vehicle, bortezomib, and bortezomib combined with MKC3946. Data represent mean ± SEM; ns, no significance; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page